Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-05-31

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Morphea in Adults and Children (MAC) cohort is the first registry for both children and adults with morphea (also known as localized scleroderma) in the country. The purpose of the registry is to learn more about morphea, specifically:

* How morphea behaves over time
* How frequently specific problems occur along with morphea (for example, arthritis)
* Whether morphea has an autoimmune background

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre

NCT04265144

Scleroderma Systemic Sclerosis

RECRUITING NA

Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis

NCT06462768

Systemic Sclerosis Other Connective Tissue Disease Systemic Lupus Erythematosus +2 more

RECRUITING

Elastography Ultrasound in Localized Scleroderma (Morphea) Study

NCT06847750

Scleroderma

ENROLLING_BY_INVITATION

Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis

NCT02636127

Scleroderma, Systemic

COMPLETED NA

Optical Coherence Tomography Imaging in Systemic Sclerosis

NCT04532151

Systemic Sclerosis Early Systemic Sclerosis Without Clinical Scleroderma and Onset < 2 Years

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Scleroderma, Localized Morphea Frontal Linear Scleroderma en Coup de Sabre Scleroderma, Circumscribed Scleroderma, Linear

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Morphea

Those having the condition morphea or other synonymous diagnosis (such as localized scleroderma, linear scleroderma, Parry-Romberg syndrome, en coup de sabre)

Morphea

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Morphea

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Scleroderma, Localized Scleroderma, Circumscribed Scleroderma, Linear Frontal Linear Scleroderma en Coup de Sabre

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient must have a clinical diagnosis of morphea confirmed by the primary investigator and by histopathological examination.
2. Ages 0-90 years old
3. Children must weigh more than 20 lbs. in order to satisfy Children's Medical Center policy for the maximum amount of blood drawn in a 24 hour period.
4. Patient or legal guardian must be able to speak and read at a 6th grade reading level.
5. Both male and female patients will be eligible
6. All races and ethnic backgrounds will be included
7. Relationships to proband: All patients with morphea will be included. A patient's family history will be reviewed and if there is a family history of morphea or systemic sclerosis then we will give the study patient the investigator's contact information and ask the family member to call the study team to answer any questions and enroll them in the study if they choose to do so.
8. Ability to give informed consent: Patients must be able to give informed consent or they will give assent with parent or guardian consent as a minor to be a part of the morphea registry.

Exclusion Criteria

\- Patients who have been coded as morphea (701.0), but do not have morphea/localized scleroderma (examples: steroid atrophy, acquired keratoderma, keloids, nephrogenic fibrosing dermopathy, systemic sclerosis, lichen sclerosis)

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes